Volume 35 Number 8S allele A in the study group was 8%, in the control group -4% (р = 0.1; chi-square). The following genotypes distribution was observed in the study group: АА -0.02; AG -0.13; GG -0.85. In the control group the following genotype distribution was observed: АА -0.01; AG -0.05; GG -0.94. Distributions corresponded to Hardy-Weinberg equilibrium.
The promise of personalized care has not always translated into improvements in patient care. There are concerns among payers that advice for certain genetic tests has been revoked, diagnostic tests can be costly, and there is fragmentation of funding of care including tests. In addition, pharmaceutical companies are seeking high prices for new targeted drugs through designating them as orphan drugs. Consequently, there is a need to integrate current knowledge about the value of genetic, biomarkers, prognostic tests and targeted drug therapies from a health authority perspective to provide future guidance. Patients (or Materials) and Methods: This will be achieved by (1) reviewing the current literature regarding personalized medicine;
(2) appraising key funding, organizational, and health care issues that need to be addressed especially from a health authority perspective; and (3) suggesting future avenues for all key stakeholder groups to enhance future funding and utilization of new personalized approaches to improve future patient care. The latter will be achieved through an iterative process. Results: Multiple findings are consolidated under headings. These include (1) general considerations incorporating definitions and the need for different approaches to progress personalized medicine; (2) knowledge about the influence of pharmacogenomics on response and toxicity of drug therapies using current examples including cases where recommendations have recently been revoked; (3) knowledge of the value of biomarker tests to target treatment approaches; (4) challenges and concerns including the potentially high cost of tests and targeted therapies and current fragmentation of funding; and (5) key issues for health care funding bodies to address to enhance funding for new diagnostic/prognostic tests as well as new targeted therapies. Guidance is given on potential ways forward for all key stakeholder groups including reviewing key medical, ethical, legal, 11.27 ± 0.968 11.54 ± 1.883 11.24 ± 0.931 12.36 ± 2.125 HAMD 17 , 6th week 9.63 ± 1.11 10.09 ± 2.095 9.54 ± 1.038 10.45 ± 2.577 F = 0.41, P = 0.741 F = 0.672, P = 0.563
